Meeting
2022 ASCO Annual Meeting
Asia subpopulation analysis from the phase III POLARIX trial.
Authors
Yuqin Song
Key Laboratory of Carcinogenesis and Transitional Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing, China
Yuqin Song , Jie Jin , Herve Tilly , Huilai Zhang , Junning Cao , Jifeng Feng , Liling Zhang , Shinya Rai , Hideki Goto , Yasuhito Terui , Won Seog Kim , Ho-Jin Shin , Jyh-Pyng Gau , Cheng-Hong Tsai , Jeff Porter Sharman , Lilian Bu , Jamie Hirata , Calvin Lee , Koji Izutsu , Jun Zhu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT03274492
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 7558)
DOI
10.1200/JCO.2022.40.16_suppl.7558
Abstract #
7558
Poster Bd #
211
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Subgroup analysis of elderly patients (pts) with diffuse large B-cell lymphoma (DLBCL) in the phase 3 POLARIX study.
First Author: Bei Hu
Poster
2012 ASCO Annual Meeting
A multicenter phase II study of bendamustine with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
First Author: Michinori Ogura
Poster
2023 ASCO Annual Meeting
Phase 3 trial of subcutaneous epcoritamab + R-CHOP versus R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL): EPCORE DLBCL-2.
First Author: Laurie Helen Sehn
Poster
2023 ASCO Annual Meeting
Glofitamab + Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from a phase Ib study.
First Author: Michael Dickinson